These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb? Patard JJ Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068 [No Abstract] [Full Text] [Related]
23. [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization]. Pomer S; Thiele R; Staehler G; Drehmer I; Löhrke H; Schirrmacher V Urologe A; 1995 May; 34(3):215-20. PubMed ID: 7610516 [TBL] [Abstract][Full Text] [Related]
24. Active and passive immunotherapy: vaccines and antibodies. Oosterwijk E; Divgi C; Bander NH BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928 [No Abstract] [Full Text] [Related]
25. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Repmann R; Wagner S; Richter A Anticancer Res; 1997; 17(4B):2879-82. PubMed ID: 9329553 [TBL] [Abstract][Full Text] [Related]
26. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Aalamian M; Fuchs E; Gupta R; Levey DL Urol Oncol; 2006; 24(5):425-33. PubMed ID: 16962495 [TBL] [Abstract][Full Text] [Related]
27. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. Gitlitz BJ; Belldegrun AS; Zisman A; Chao DH; Pantuck AJ; Hinkel A; Mulders P; Moldawer N; Tso CL; Figlin RA J Immunother; 2003; 26(5):412-9. PubMed ID: 12973030 [TBL] [Abstract][Full Text] [Related]
29. Tailor-made renal cell carcinoma vaccines. Dranoff G Cancer Cell; 2012 Sep; 22(3):287-9. PubMed ID: 22975372 [TBL] [Abstract][Full Text] [Related]
30. Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination. Yasukawa M; Ochi T; Fujiwara H Ann Oncol; 2010 Oct; 21(10):2122-2124. PubMed ID: 20860992 [No Abstract] [Full Text] [Related]
31. Immunotherapy for renal cell cancer. Yang JC; Childs R J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543 [TBL] [Abstract][Full Text] [Related]
33. [Efficacy of vaccination in the adjuvant treatment of cancer of the kidney]. Fayette J Bull Cancer; 2004 Mar; 91(3):211. PubMed ID: 15171044 [No Abstract] [Full Text] [Related]
37. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma? Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207 [TBL] [Abstract][Full Text] [Related]
38. [New trends in the diagnosis and treatment of renal cell carcinoma]. Zisman A Harefuah; 2002 Aug; 141(8):713-7, 761. PubMed ID: 12222136 [TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma. Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539 [TBL] [Abstract][Full Text] [Related]
40. Interferons in renal-cell carcinoma: status and prospects. De Mulder PH; Debruyne FM; Beniers AJ Prog Clin Biol Res; 1990; 348():49-59. PubMed ID: 1696737 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]